Search Results

Your search for Joshua Spendlove, MD, and E. David Crawford, MD,Joshua Spendlove, MD, and E. David Crawford, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / December 15 2011

Reflections from The ASCO Post

The editors gratefully acknowledge all contributors to The ASCO Post and thank the columnists who contributed to Volume 2, January–December 2011: Al B. Benson III, MD, FACP Richard Boxer, MD, FACS Carlton G. Brown, RN, PhD, AOCN Barrie R. Cassileth, PhD E. David Crawford, MD Emil J. Freireich, MD, ...

prostate cancer

By Joshua Spendlove, MD, and E. David Crawford, MD / December 15 2011

Prostate Cancer Screening Reconsidered

Prostate cancer is the most prevalent nonskin cancer in men. An estimated 16% of men are diagnosed with prostate cancer, yet only 3% of men die from it.1 Unlike other cancers, prostate cancer is associated with a prolonged lead-time, meaning it can take anywhere from 5 to 12 years to become...

Nov

Today In Oncology

Search Results

Your search for Joshua Spendlove, MD, and E. David Crawford, MD,Joshua Spendlove, MD, and E. David Crawford, MD matches 2 pages

Reflections from The ASCO Post

Prostate Cancer Screening Reconsidered

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC